Abiopharma

New Form 8-K - Entera Bio Ltd. Filed: 2025-05-09 AccNo: 0001178913-25-001673 Size: 342 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

New Form 4 - Twist Bioscience Corp Filed: 2025-05-09 AccNo: 0001214659-25-007287 Size: 5 KB

New Form DEFR14A - Inmune Bio, Inc. Filed: 2025-05-09 AccNo: 0001213900-25-041516 Size: 1 MB

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

New Form SCHEDULE 13G/A - INVO Fertility, Inc. Filed: 2025-05-09 AccNo: 0001213900-25-041513 Size: 11 KB

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Oculis Publishes Invitation to the Annual General Meeting

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Oculis birtir boð á aðalfund

New Form SCHEDULE 13G/A - Dermata Therapeutics, Inc. Filed: 2025-05-09 AccNo: 0001213900-25-041511 Size: 11 KB

New Form 8-K - ReShape Lifesciences Inc. Filed: 2025-05-09 AccNo: 0001104659-25-046717 Size: 271 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form SCHEDULE 13G/A - MUSTANG BIO, INC. Filed: 2025-05-09 AccNo: 0001213900-25-041510 Size: 11 KB

New Form 144 - Spok Holdings, Inc Filed: 2025-05-09 AccNo: 0001958244-25-003072 Size: 8 KB

New Form 144 - TransMedics Group, Inc. Filed: 2025-05-09 AccNo: 0001950047-25-002824 Size: 4 KB